RESUMO
We report on the first direct measurement of the proton separation energy for the proton-unbound nucleus (69)Br. Bypassing the (68)Se waiting point in the rp process is directly related to the 2p-capture rate through (69)Br, which depends exponentially on the proton separation energy. We find a proton separation energy for (69)Br of Sp((69)Br )= -785(-40)(+34) keV; this is less bound compared to previous predictions which have relied on uncertain theoretical calculations. The influence of the extracted proton separation energy on the rp process occurring in type I x-ray bursts is examined within the context of a one-zone burst model.
Assuntos
Anticorpos Anti-Hepatite A/sangue , Antígenos da Hepatite A/imunologia , Vacinas contra Hepatite A/uso terapêutico , Vírus da Hepatite A Humana/imunologia , Hepatite A/prevenção & controle , Militares , Adolescente , Adulto , Hepatite A/imunologia , Anticorpos Anti-Hepatite A/imunologia , Vacinas contra Hepatite A/administração & dosagem , Humanos , Testes Sorológicos , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/uso terapêuticoRESUMO
The authors present the results of study of arbidolum therapeutic-and-prophylactic effectiveness in acute respiratory viral infections (ARVI) under conditions of military staff with determination of economic expediency. Coefficient of effectiveness of arbidolum prophylactic use was 25% and efficiency index--1.33. In experimental group the ARVI complicated forms were noted in 3% of the patients and in control group--in 5%. Due to decreased expenses on the treatment of non-complicated and complicated ARVI forms the cost of therapy of one servicemen in the first group was 290.6 rubles, in the second group--323 rubles, in the third group--336 rubles and in the fourth group--368 rubles. The results of investigation have shown the significant advantage of arbidolum therapeutic-and-prophylactic use compared with other variants. Its use permitted to decrease the febrile period, to reduce the manifestation of symptoms of intoxication and affection of upper respiratory tract.
Assuntos
Antivirais/uso terapêutico , Indóis/uso terapêutico , Militares , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/prevenção & controle , Viroses/tratamento farmacológico , Doença Aguda , Adolescente , Adulto , Humanos , Masculino , Moscou , Infecções Respiratórias/economia , Resultado do Tratamento , Viroses/prevenção & controleRESUMO
The epidemiological effectiveness of interferon inductor "Poludanum" produced by "LENS Pharm" (Russia) for prevention of acute respiratory viral infections was tested. The drug was administered among the students of Military Medical Academy (101 students) according to scheme 1: in a nose, 3 drops in each nasal passage two times per week during 4 weeks, with 2 week interruption then the scheme was repeated. The scheme 2 included 3 drops in each nasal passage once a week during 10 weeks (95 students). The placebo group (96 students) received the distilled water. In the students receiving "Poludanum" according to scheme 1 the incidence of acute respiratory diseases (ARD) was significantly lower than in the control group (p = 0.058). The coefficient of effectiveness was 50%, i.e. the incidence has decreased in two times. The use of poludanum according to scheme 2 caused no decrease in ARD incidence.
Assuntos
Antivirais/uso terapêutico , Influenza Humana/prevenção & controle , Indutores de Interferon/uso terapêutico , Militares , Polirribonucleotídeos/uso terapêutico , Doenças Respiratórias/prevenção & controle , Doença Aguda , Humanos , Influenza Humana/epidemiologia , Doenças Respiratórias/epidemiologiaRESUMO
The results obtained during the study of antigeneity of inactivated vaccines against hepatitis A ("Avaxim", France; "Hep-A-in-VAC", Russia; "Havrix", Belgium) used in troop units and RF MD institutions are presented in the article. The aim of the investigation is choice of the drug that provides the production of antibody protective levels in maximally short periods. It is very important for the army collectives sent to the zones of armed conflicts and HAV epidemic centres. It is shown that the most acceptable vaccine is "Avaxim" that provides the highest percentage of seroconversion (93.75%) with antibody level not less than 125 mIU/ml. It is recommended to consider this level as the protective one in conditions of army collectives.